Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

CEO Sofia Heigis interviewed by Redeye

January 19, 2026 – Redeye’s analyst Richard Ramanius interviews Sofia regarding the new financial goals from January 2026. The interview is held in Swedish.

Watch the interview

Webcast in conjunction to Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

January 16, 2026 – Oncopeptides yesterday announced the net sales for the fourth quarter of 2025 and updates its cash-flow expectations. The company hosts a webcast and Q&A session aimed at investors, analysts and media today, Friday, January 16 at 09.00 CET.

Read more and watch the webcast

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

Research shows that Pepaxti is effective in high-risk myeloma

December 31, 2025

Oncopeptides recently announced new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations.

Read more

NKEngage Grant Project Completed

November 12, 2025

The NKEngage project, funded under the Eurostars program (Vinnova/Eureka), has successfully concluded after achieving its research goals.

Read more

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

November 11, 2025

Oncopeptides today announced that a panel of leading multiple myeloma experts has published clinical recommendations for the optimal use of melflufen (branded in Europe as Pepaxti) in Annals of Hematology.

Read more

Investor news

CEO Sofia Heigis interviewed by Redeye

January 19, 2026

Read more

Webcast in conjunction to Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

January 16, 2026

Read more

Oncopeptalks – Commercialization, pipeline and ASH

December 16, 2025

Read more

All Company news

All Science news

All Investor news

Press release - January 15, 2026

Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

Read press release

Latest press releases

All press releases

Upcoming events

2026-01-19 - 2026-02-18

Silent period

Other

2026-02-19

Year-end report 2025

Report

2026-04-13 - 2026-05-12

Silent period

Other

Full calendar
CEO Sofia Heigis - Oncopeptides AB

Released November 5, 2025

Oncopeptides publishes Q3 report 2025

Read report

Download

“The third quarter of 2025 was a solid and strategically important period for Oncopeptides as we reached several important milestones for continued growth into 2026”

CEO Sofia Heigis

 

See the Webcast

The presentation as PDF

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Year-end Report 2025 will be published February 19, 2026

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Oncopeptides via e-mail